文献速递泌尿生殖腹部MR

根治性前列腺切除术后前列腺癌患者最终Gleason评分、PI-RADS v2评分、ADC值、PSA水平与肿瘤直径之间关系的评估

Evaluation of relationships between the final Gleason score, PI-RADS v2 score, ADC value, PSA level, and tumor diameter in patients that underwent radical prostatectomy due to prostate cancer.
PubMed 文献 · Radiol Med · 2020-04-07

回顾性分析因前列腺癌行根治性前列腺切除术患者的mpMRI,比较临床显著(GS≥7)与不显著(GS≤6)前列腺癌的PSA、肿瘤ADCmin、肿瘤直径及PI-RADS评分,并按中央腺与外周腺肿瘤分别分析相关性并计算鉴别两组的切点值。

要点

  • 中央腺肿瘤中PSA与PI-RADS评分在临床显著与不显著组间无显著差异(p>0.05),ADCmin与肿瘤直径有显著差异(p<0.05)。
  • 外周腺肿瘤中PSA、ADCmin、肿瘤直径及PI-RADS评分在两组间均有显著差异(p<0.05)。
  • 鉴别临床显著与不显著肿瘤的切点值:外周腺肿瘤直径13.5 mm、ADCmin 0.709×10-3 mm2/s、PSA 8.47 ng/ml;中央腺肿瘤直径19 mm、ADCmin 0.874×10-3 mm2/s、PSA 11.10 ng/ml。

核心结论

  • 现行PI-RADS v2评分系统在区分中央腺肿瘤的临床显著与不显著组时可能不足。
  • 应为中央腺和外周腺肿瘤分别确定肿瘤直径的切点值。
  • 肿瘤ADCmin值可作为预测参数。
  • 外周腺肿瘤的PSA切点值应保持较低。

研究设计与样本

  • 回顾性评估因前列腺癌行根治性前列腺切除术患者的mpMRI检查。
  • 根据最终Gleason评分将病灶分为临床显著组(GS≥7)与不显著组(GS≤6)。
  • 采用Student t检验比较两组PSA值、肿瘤ADCmin值、肿瘤直径及PI-RADS评分。
  • 采用Pearson相关分析评估外周腺肿瘤各参数相关性,采用Spearman相关分析评估中央腺肿瘤各参数相关性。
  • 采用ROC分析评估肿瘤ADCmin、直径及PSA值鉴别临床显著与不显著肿瘤的效能。

诊断标准与关键数值

  • 中央腺与外周腺肿瘤中,PSA水平、肿瘤直径、PI-RADS评分、ADCmin值与Gleason评分之间均存在不同程度(弱、中等、强)的相关性。
  • 中央腺肿瘤中两组PSA值与PI-RADS评分无显著差异(p>0.05),ADCmin值与肿瘤直径有显著差异(p<0.05)。
  • 外周腺肿瘤中所有参数均有显著差异(p<0.05)。
  • 鉴别临床显著与不显著肿瘤的切点值:外周腺肿瘤直径13.5 mm、ADCmin 0.709×10-3 mm2/s、PSA 8.47 ng/ml;中央腺肿瘤直径19 mm、ADCmin 0.874×10-3 mm2/s、PSA 11.10 ng/ml。

临床应用与阅片要点

  • 阅片时可参考中央腺肿瘤直径19 mm、ADCmin 0.874×10-3 mm2/s、PSA 11.10 ng/ml的切点值辅助区分临床显著与不显著肿瘤。
  • 阅片时可参考外周腺肿瘤直径13.5 mm、ADCmin 0.709×10-3 mm2/s、PSA 8.47 ng/ml的切点值辅助区分临床显著与不显著肿瘤。
  • 作者认为现行PI-RADS v2评分系统在区分中央腺肿瘤的临床显著与不显著组时可能不足。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

INTRODUCTION: This study aimed to investigate the relationship between the serum PSA level, Gleason score (GS), PI-RADS v2 score, tumor ADCmin value, and the largest tumor diameter in patients that underwent radical prostatectomy (RP) due to prostate cancer (PCa) and to comparatively evaluate the variables of these parameters in clinically significant and insignificant PCa groups.

MATERIALS AND METHODS: The mpMRI examinations of the patients who underwent RP due to PCa were retrospectively evaluated. According to the final GS, the lesions were divided into two groups as clinically significant (GS ≥ 7) and insignificant (GS ≤ 6). The PSA value, tumor ADCmin value, tumor diameter, and PI-RADS score were compared between the clinically significant and nonsignificant PCa groups using Student's t-test. The correlations between the serum PSA level, GS, PI-RADS v2 score, tumor ADCmin value, and tumor diameter were evaluated separately (Pearson's correlation analysis was used for peripheral gland tumors, and Spearman's correlation analysis for central gland tumors). A ROC analysis was undertaken to evaluate the efficacy of the tumor ADCmin, diameter and PSA values in differentiating clinically significant and nonsignificant tumors.

RESULTS: In both central and peripheral gland tumors, there was a correlation between the PSA level, tumor diameter, PI-RADS score, ADCmin value, and GS at various levels (poor, moderate, and high). In central gland tumors, there was no significant difference between the two groups in terms of the PSA value and PI-RADS scores (p > 0.05), but the ADCmin value and diameter of the tumor significantly differed (p < 0.05). For peripheral gland tumors, significant differences were observed in all parameters (p < 0.05). The cut-off values for the peripheral and central gland tumors are as follows: lesion diameter, 13.5 mm and 19 mm; tumor ADCmin, 0.709 × 10-3 mm2/s and 0.874 × 10-3 mm2/s; and PSA level, 8.47 ng/ml and 11.10 ng/ml, respectively.

CONCLUSION: The current PI-RADS v2 scoring system can be inadequate in distinguishing clinically significant and insignificant groups in central gland tumors. A separate cut-off value of the tumor diameter should be determined for central and peripheral gland tumors. Tumor ADCmin values can be used as a predictive parameter. The PSA cut-off value should be kept lower in peripheral gland tumors.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Gündoğdu E, Emekli E, Kebapçı M, et al. Evaluation of relationships between the final Gleason score, PI-RADS v2 score, ADC value, PSA level, and tumor diameter in patients that underwent radical prostatectomy due to prostate cancer. Radiol Med. 2020. PMID: 32266690. doi:10.1007/s11547-020-01183-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。